• 1 Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China. Electronic address:
  • 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France
  • 3 Shanghai Chest Hospital, Shanghai, P.R. China
  • 4 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, P.R. China
  • 5 Department of Internal Medicine 3, Wakayama Medical University, Wakayama, Japan
  • 6 Seoul National University Hospital, Seoul, Korea
  • 7 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
  • 8 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
  • 9 Department of Radiotherapy & Oncology, Prince Court Medical Centre, Kuala Lumpur, Malaysia
  • 10 Faculty of Medicine, Department of Thoracic Surgery, Kindai University, Osaka-Sayama, Japan
  • 11 Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 12 Department of Haematology-Oncology, National University Hospital, Singapore, Singapore
  • 13 Division of Haematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung, Taiwan
  • 14 Faculty of Medicine, Department of Clinical Oncology, University of Malaya, Kuala Lumpur, Malaysia
  • 15 Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • 16 ESMO, Lugano, Switzerland
Ann. Oncol., 2019 02 01;30(2):171-210.
PMID: 30596843 DOI: 10.1093/annonc/mdy554


The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications